Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalWomen's HealthFertilityTrial Update

Phase II Trial Investigates Vitamin D's Impact on Menstrual Cycle Health

The inVitD Trial is pivotal as it explores the relationship between vitamin D and menstrual health, potentially reshaping guidelines for fertility treatments. Positive outcomes could lead to new product development and marketing strategies in women's health.

Published: June 18, 2026
Updated: June 18, 2026
Author: Humanexa Intelligence
Therapeutic area: Women's Health / Fertility
Asset: Fertility
Trial SummaryCLN

Phase II

Women's Health / Fertility

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The inVitD Trial is pivotal as it explores the relationship between vitamin D and menstrual health, potentially reshaping guidelines for fertility treatments. Positive outcomes could lead to new product development and marketing strategies in women's health.

Why it matters

The inVitD Trial is pivotal as it explores the relationship between vitamin D and menstrual health, potentially reshaping guidelines for fertility treatments. Positive outcomes could lead to new product development and marketing strategies in women's health.

What changed

Trial Update

Analysis

The inVitD Trial aims to assess the effects of vitamin D supplementation on menstrual cycle hormones in women aged 19-40.

The inVitD Trial is pivotal as it explores the relationship between vitamin D and menstrual health, potentially reshaping guidelines for fertility treatments. Positive outcomes could lead to new product development and marketing strategies in women's health.

Monitor recruitment progress and initial findings regarding hormone levels and menstrual cycle regularity.

Related companies & assets

Assets

  • Fertility →

Sources & Humanexa intelligence

Source links

  • The Investigation of Vitamin D and Menstrual Cycles Trial, the inVitD Trial ↗
  • Phase II Trial Investigates Vitamin D's Impact on Menstrual Cycle Health ↗

Related Humanexa pages

  • Phase II Trial Investigates Vitamin D's Impact on Menstrual Cycle Health →

Related signals

Trial SummaryCLN

Phase III

gastric cancer therapies

Status

Active

Signal Score

8.4

Clinicalhigh signal

FTO/BCL6 Axis Identified as Therapeutic Target in Gastric Cancer Progression

FTO-mediated demethylation of BCL6 promotes gastric cancer progression by inhibiting ferroptosis.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

epithelial ovarian cancer

Status

Active

Signal Score

8.4

Clinicalhigh signal

Targeted PEGylated PLGA Nanoparticles Enhance Hesperidin Delivery in Ovarian Cancer

Hesperidin-loaded PEGylated PLGA nanoparticles demonstrate improved dissolution and cytotoxicity in EOC models.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.